RemeGen scores out-licensing triple play with AbbVie deal
The agreement marks the drug maker’s third such transaction since last year, setting records for both its largest upfront payment and highest total deal value Key Takeaways: PD-1/VEGF bispecific antibodies…
So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
-
BRIEF: Everest Medicines advances with major licensing deal, new drug application approval
1952.HK
- Ming Yu seeks a share of the drug sector limelight
-
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK600196.SHG
